NVO Stock Quote Price and Forecast | CNN

NVO

Novo Nordisk A/S Sponsored ADR Class B

Key terms

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Sector

Industry

Employees

Founded

Website

Key stock statistics

1-day range

52-week range

Market cap

P/E ratio

Next earnings date

Dividend yield

Ex-dividend date

Dividend pay date

Key terms

Smart score

Apr 12 12:53pm ET LLY, NVO: Obesity Drugs May Help with Parkinson’s by TipRanks Apr 12 4:47am ET Novo Nordisk initiated with an Outperform at BMO Capital by TipRanks Apr 12 4:25am ET Buy Rating for Novo Nordisk: Strong Growth Potential Driven by Strategic Partnerships and Innovative Pipeline by TipRanks Apr 08 11:57am ET Novo Nordisk Launches Major Share Buyback by TipRanks Apr 05 12:40pm ET Viking Therapeutics Stock (NASDAQ:VKTX): Analysts Stay Bullish on 2024’s Top Mid-Cap by TipRanks Apr 02 8:27am ET Novo Nordisk Initiates Multi-Billion Share Buyback by TipRanks Apr 01 1:57pm ET Novo Nordisk Launches Multi-Billion Share Buyback by TipRanks Mar 31 6:52pm ET Omega Therapeutics price target lowered to $7 from $12 at Chardan by TipRanks Mar 28 10:39am ET Novo Nordisk Under Fire, Post-Ozempic Study by TipRanks Mar 27 12:58pm ET Ozempic manufacturing costs could be 89c per month, study finds by TipRanks Mar 25 11:27am ET Novo Nordisk Updates Corporate Governance by TipRanks Mar 25 6:10am ET Novo Nordisk to acquire Cardior Pharmaceuticals for up to EUR 1.025B by TipRanks Mar 22 7:30am ET Argus cuts Pfizer to Hold on headwinds to revenue growth by TipRanks Mar 22 7:00am ET Novo Nordisk’s Awiqli® Set to Transform Diabetes Care by TipRanks Mar 21 1:27pm ET Novo Nordisk Thrives with Record Patient Reach by TipRanks Mar 21 11:58am ET Novo Nordisk receives positive CHMP opinion on Awiqli for diabetes by TipRanks Mar 21 11:00am ET Medicare Part D may cover Novo obesity drug, WSJ reports by TipRanks Mar 20 12:34pm ET CBO analyst comments on obesity drugs similar to October 2023 report by TipRanks Mar 20 12:24pm ET Eli Lilly, Novo Nordisk lower after CBO analyst comments on obesity drugs by TipRanks Mar 20 12:20pm ET Lilly, Novo lower after CBO analyst says obesity drugs could raise deficit by TipRanks Mar 20 6:20am ET Wall Street Analysts Are Bullish on Top Healthcare Picks by TipRanks Mar 18 2:52pm ET Novo Nordisk price target raised to DKK 900 from DKK 850 at Berenberg by TipRanks Mar 18 12:27pm ET Novo Nordisk Advances Share Buyback Program by TipRanks Mar 18 10:41am ET Oprah to host TV special discussing weight loss, CNN reports by TipRanks Mar 15 4:47pm ET Eli Lilly’s (NYSE:LLY) Weight-Loss Drug Outshines Wegovy for First Time by TipRanks Mar 15 4:55am ET Piper Sandler healthcare/pharma analysts hold analyst/industry conference call by TipRanks Mar 14 12:50pm ET Cantor Fitzgerald biotech analysts hold an analyst/industry conference call by TipRanks Mar 14 11:41am ET Cantor Fitzgerald biotech analysts hold an analyst/industry conference call by TipRanks Mar 13 11:00am ET European Stocks: Unnoticed Records, Overlooked Opportunities by TipRanks Mar 13 7:26am ET Corbus Pharmaceuticals price target raised to $58 from $51 at Oppenheimer by TipRanks Mar 13 5:24am ET Novo Nordisk downgraded to Neutral from Outperform at Oddo BHF by TipRanks

Yesterday 10:00am ET Novo Nordisk and Ginkgo Bioworks Are Teaming Up. Here's Why That's Bullish for Both Stocks. by Motley Fool Yesterday 9:30am ET Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF? by Motley Fool Yesterday 9:00am ET Better Growth Play: Merck or The Vanguard Growth Index Fund? by Motley Fool Apr 08 5:55am ET Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It. by Motley Fool Apr 07 7:15am ET Could This New Development Soon Buoy Eli Lilly and Novo Nordisk Stock? by Motley Fool Apr 04 7:30am ET After Wegovy's Approval to Treat Heart Disease, Novo Nordisk Continues to Make Moves by Motley Fool Apr 04 4:55am ET Could This 1 Detail Help Viking Therapeutics Top Eli Lilly and Novo Nordisk in the Weight Loss Drug Market? by Motley Fool Apr 03 4:31pm ET Why Eli Lilly Stock Topped the Market Today by Motley Fool Apr 02 5:50am ET Could Viking Therapeutics Stock Be a Millionaire Maker? by Motley Fool Apr 02 5:10am ET Is It Too Late to Buy Eli Lilly Stock? by Motley Fool Apr 01 4:30am ET Meet The "Magnificent Seven" of Healthcare Stocks by Motley Fool Mar 31 6:14pm ET Is Novo Nordisk the Best Healthcare Stock for You? by Motley Fool Mar 31 8:15am ET Diversifying Into This Key Market Is 1 More Reason to Buy Novo Nordisk Stock by Motley Fool Mar 28 6:50am ET Prediction: This Will Be the Next "Magnificent Seven" Stock by Motley Fool Mar 26 10:35am ET Novo Nordisk and Nvidia Just Partnered on AI. Is the Stock a Buy? by Motley Fool Mar 26 5:51am ET Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics? by Motley Fool Mar 25 9:07am ET Uncovering Hidden Gems: 1 AI-Powered Healthcare Stock Set to Dominate the Market by Motley Fool Mar 25 6:25am ET Novo Nordisk and Eli Lilly May Finally Have Some Real Competition by Motley Fool Mar 24 9:15am ET Is Viking Therapeutics Stock a Millionaire Maker? by Motley Fool Mar 22 10:30am ET With Shares Trading Near All-Time Highs, Is Now the Time to Take Profits in Novo Nordisk? by Motley Fool Mar 22 7:15am ET Did Eli Lilly Just One-Up Novo Nordisk? by Motley Fool Mar 21 10:15am ET Novo Nordisk's New Weight Loss Drug Could Be Better Than Ozempic and Wegovy by Motley Fool Mar 20 8:30am ET Will Novo Nordisk Overtake Eli Lilly as the Most Valuable Healthcare Stock? by Motley Fool Mar 19 10:00am ET Is Novo Nordisk on the Verge of Another Blockbuster Drug? by Motley Fool Mar 19 7:30am ET Did Novo Nordisk Just Get a Jump on Eli Lilly? by Motley Fool Mar 19 5:50am ET Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win? by Motley Fool Mar 17 2:28pm ET Novo Nordisk Isn't in The "Magnificent Seven," but Here's Why I Think It Should Be by Motley Fool Mar 17 9:46am ET Novo Nordisk Is Already Working on Wegovy's Successor -- Time to Buy? by Motley Fool Mar 17 9:00am ET 3 Unstoppable Stocks You Can Buy Now Without Any Hesitation by Motley Fool Mar 17 5:50am ET Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy? by Motley Fool Mar 17 3:24am ET Eli Lilly Taps Amazon to Deliver Its Weight Management Blockbuster. Is It Time to Buy the Pharma Stock? by Motley Fool

No recent press releases are available for NVO

1-year income & revenue

Key terms

analyst rating

buy
hold
sell

1-year stock price forecast

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Donald Trump might no longer own a majority of TMTG after a new public share offering.

Joe Raedle/Getty Images

Trump stock tanks after announcing massive share sale

1040 US Individual Income Tax Return Form

Nora Carol Photography/Moment RF/Getty Images

Three ways investors can minimize their tax payments

People walk past the New York Stock Exchange (NYSE) on April 10, 2024 in New York City.

Spencer Platt/Getty Images

Dow closes nearly 500 points lower on fears of potential Iranian attack on Israel

JPMorgan beat earnings expectations this Friday, unofficially kicking off the first quarter earnings season.

Win McNamee/Getty Images

Jamie Dimon says chance of a bad economy is ‘higher than other people think’